AzTrials
AzTrials

Relapsed or Refractory Multiple MyelomaPhase 1/2NCT07681596

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 study testing AZD4045, Daratumumab and Aldesleukin in people with Relapsed or Refractory Multiple Myeloma, run by AstraZeneca at 12 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Relapsed or Refractory Multiple Myeloma
What is being tested?
AZD4045, Daratumumab and Aldesleukin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
101 participants
Where
12 sitesin 2 countries
Study dates
27 Jul 2026to 6 Mar 2031
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant must be 18 years or older at the time of signing the informed consent form.
  • Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria.
  • Participant must have one or more of the following measurable disease criteria:
  • Serum M-protein level ≥ 1.0 g/dL.
  • Urine M-protein ≥ 200 mg/24 h.
  • Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio.
Show all 11Show fewer
  • ECOG performance score of 0 to 1.
  • Participant must have screening bone marrow aspirate and/or archival sample adequate for clonal sequence calibration for MRD. An archival sample obtained from any time prior is acceptable.
  • Participant must have adequate organ and bone marrow function.
  • Participant must have received at least 3 prior classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody
  • Participant must have documented evidence of PD by IMWG 2016 criteria based on Investigator's determination during or after the most recent line of therapy

Who cannot join

  • Participant has a history of any grade IEC-HS and/or history of Grade ≥ 3 CRS and/or Grade ≥ 2 neurotoxicities during prior CAR-T cell therapy or T cell engaging therapy.
  • Participant has ongoing toxicity from previous anti-cancer therapy that did not resolve to baseline levels or to Grade ≤ 1 with the exception of alopecia or peripheral neuropathy.
  • Participant has a known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
  • Participant has systemic immunoglobulin light chain amyloidosis, active plasma cell leukaemia (presence of ≥ 5% of circulating plasma cells on a conventional peripheral blood smear) at time of screening, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome.
  • Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
  • Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
Show all 41Show fewer
  • Participant has significant neurological or psychiatric condition (active or history of).
  • Participant is positive for any of the following:
  • HIV (with exceptions)
  • Chronic or active hepatitis B
  • Active hepatitis C
  • Participant has clinically significant cardiovascular disease, including but not limited to:
  • Myocardial infarction within 6 months prior to eligibility confirmation, or an unstable or uncontrolled disease/condition related to or affecting cardiac function.
  • Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.
  • Congestive heart failure Class III or IV.
  • Impaired cardiac function (LVEF < 45%).
  • Participant has any other significant medical condition which, in the opinion of the Investigator, places the participant at an unacceptable risk for treatment-related complications, could interfere with the successful or safe delivery of therapy, or could interfere with evaluation of study intervention or interpretation of participant safety or study results. These include but are not limited to:
  • Serious active or uncontrolled infection.
  • Requirement of supplemental oxygen to maintain oxygen saturation.
  • Active autoimmune disease or a history of autoimmune disease within 2 years.
  • Inflammatory bowel disease requiring treatment within the past 5 years or other clinically significant gastrointestinal condition.
  • Participant received live, attenuated vaccine within 28 days prior to eligibility confirmation
  • Participant has undergone major surgery within 28 days prior to eligibility confirmation
  • Concurrent enrolment in another clinical study (unless the study is observational, or the participant is in the follow-up period of an interventional study).
  • Participant has a known life-threatening allergy, hypersensitivity, intolerance, or a contraindication to any study intervention or their excipients.
  • Participant received any prior CAR-T or CAR-NK therapy directed at any target within 6 months prior to eligibility confirmation.
  • Participant received any prior TCE therapy directed at any target within 6 months prior to eligibility confirmation.
  • Participant received any prior BCMA-targeted treatment within 6 months prior to eligibility confirmation.
  • Participant with a history of refractoriness to the most recent BCMA-targeted treatment received as defined as PD on or within 60 days of last dose or non-responsiveness (ie, did not achieve at least minimal response) on therapy.
  • Participant received prior allogeneic stem cell transplant at any time.
  • Participant received autologous stem cell transplant within 3 months prior to eligibility confirmation.
  • Participant received radiation therapy for treatment of plasmacytoma within 14 days before eligibility confirmation.
  • Participant received prior anti-tumour therapy as follows prior to the first dose of lymphodepletion:
  • Within 7 days:
  • Immunomodulatory or cereblon E3 ligase modulatory drugs. b) Within 14 days:
  • PI therapy.
  • Monoclonal antibody treatment for MM.
  • Cytotoxic therapy.
  • Other systemic anti-myeloma therapy.
  • Radiation. c) Within 14 days or at least 5 half-lives, whichever is longer:
  • Targeted therapy, epigenetic therapy, investigational drug or used an invasive investigational medical device.

Trial locations and contacts

12 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

12 sites in 2 countries

United States10 sites, 8 recruiting

  • Research Site

    Atlanta, Georgia, 30322

    Not yet recruiting

  • Research Site

    Cleveland, Ohio, 44195

    Withdrawn

  • Research Site

    Denver, Colorado, 80218

    Not yet recruiting

  • Research Site

    Duarte, California, 91010

    Recruiting

  • Research Site

    Hackensack, New Jersey, 07601

    Not yet recruiting

  • Research Site

    Houston, Texas, 77030

    Recruiting

  • Research Site

    Milwaukee, Wisconsin, 53226

    Withdrawn

  • Research Site

    Nashville, Tennessee, 37203

    Not yet recruiting

  • Research Site

    St Louis, Missouri, 63110

    Not yet recruiting

  • Research Site

    Tampa, Florida, 33612

    Not yet recruiting

Other trials in United States

Australia2 sites, 2 recruiting

  • Research Site

    Camperdown, 2050

    Not yet recruiting

  • Research Site

    East Melbourne, 3002

    Recruiting

Other trials in Australia

About this study

Official title: A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Read the detailed description

This modular study aims to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of AZD4045 in participants with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose of AZD4045. Module 1 consists of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin.

Being tested
AZD4045, Daratumumab, Aldesleukin
Keywords
Multiple myeloma, Relapsed or refractory multiple myeloma, RRMM, Relapsed multiple myeloma, Refractory multiple myeloma, AZD4045, CAR-T, CART, Allogeneic
Medical subject headings
Recurrence, Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AZD4045Biological

    Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)

  • DaratumumabDrug

    Anti-CD38 monoclonal antibody

  • AldesleukinDrug

    Recombinant human IL-2

Study groups in NCT07681596
Study groupRoleWhat they receive
Module 1: AZD4045 monotherapyExperimentalNot described
Receives: Biological: AZD4045
Module 1: AZD4045 in association with daratumumab and aldesleukinExperimentalNot described
Receives: Biological: AZD4045; Drug: Daratumumab; Drug: Aldesleukin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse events (AEs) and serious AEs (SAEs)

    Incidence and severity of adverse events (AEs) and serious AEs (SAEs)

    Measured: Through study completion, an average of 2 years

  2. Dose-limiting toxicities (DLT)

    Incidence and severity of dose-limiting toxicity (DLT) events

    Measured: 28 days

Secondary outcomes (11)

  1. Efficacy - Objective Response Rate (ORR)

    Defined as proportion of participants who achieve an overall response of PR or better according to the IMWG 2016 criteria

    Measured: Through study completion, an average of 2 years

  2. Efficacy - Complete Response Rate (CRR)

    Defined as proportion of participants who achieve a CR/sCR response according to the to the IMWG 2016 criteria

    Measured: Through study completion, an average of 2 years

  3. Efficacy - Duration of Response (DOR)

    Defined as the time from first documented confirmed response until date of documented PD per IMWG 2016 criteria or death due to any cause, whichever occurs first

    Measured: Through study completion, an average of 2 years

  4. Efficacy - Time to Response (TTR)

    Defined as the time from infusion until the date of first documented objective response, as assessed per IMWG 2016 criteria

    Measured: Through study completion, an average of 2 years

  5. Cellular kinetics - Quantification of CAR transgene levels

    Determination of transgene level

    Measured: Through study completion, an average of 2 years

  6. Cellular kinetics - Tmax

    Time to reach maximum AZD4045 level

    Measured: Through study completion, an average of 2 years

  7. Cellular kinetics - Cmax

    Maximum AZD4045 level

    Measured: Through study completion, an average of 2 years

  8. Cellular kinetics - AUC0-28d

    Area under the concentration time-curve of AZD4045 level

    Measured: 0 - 28 days

  9. Cellular kinetics - Tlast

    Time to last quantifiable concentration of AZD4045 level

    Measured: Through study completion, an average of 2 years

  10. Cellular kinetics - Clast

    Observed concentration of AZD4045 at last quantifiable concentration

    Measured: Through study completion, an average of 2 years

  11. Cellular kinetics - AUClast

    Area under the concentration time-curve of AZD4045 level

    Measured: Through study completion, an average of 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2026
  2. Study start27 Jul 2026
  3. Primary completion6 Mar 2031 (estimated)
  4. Study completion6 Mar 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
101 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07681596
Sponsor's protocol ID
D7540C00001
Status last verified
Oct 2026
First submitted
26 Jun 2026
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing AZD4045, Daratumumab and Aldesleukin in people with Relapsed or Refractory Multiple Myeloma, run by AstraZeneca at 12 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 41 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse events (AEs) and serious AEs (SAEs) (time frame: Through study completion, an average of 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07681596.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in